Search
Selected Filter
Displaying 11–20 of 199 research results
-
Researchers Report Six-Month Results from Biogen-Sponsored XLRP Gene Therapy Clinical Trial
Vision improvements observed with medium and high doses
-
Foundation Joins the Institute for Gene Therapies, a Newly Formed Advocacy Organization
IGT to accelerate gene therapy development and patient access
-
Genetic Testing for Inherited Retinal Diseases through the Foundation’s Open Access Program
The benefits of genetic testing for IRD patients, how to participate in the Foundation’s Open Access program, and what to expect from the genetic testing process.
-
AGTC Reports Positive Six-Month Results for XLRP Phase 1/2 Gene Therapy Trial
The company is planning a Phase 3, pivotal trial for end of 2020
-
First Human Study in US for Induced Pluripotent Stem Cells to be Launched for Advanced Dry AMD
Currently there are no treatments for Advanced Dry AMD, also known as GA, which can lead to significant central vision loss
-
First Patient Receives ProQR’s AON Therapy in Clinical Trial for RP Caused by RHO-P23H Mutation
The trial becomes ProQR’s third human study for inherited retinal disease therapies
-
Families and Scientists Meet to Discuss Therapy Development for People with RDH12 Mutations
Proof-of-concept for RDH12 gene therapy demonstrated in mouse model
-
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Phase 1/2a human study will evaluate neural progenitors for preserving vision
-
AGTC Announces Development of Stargardt Disease Gene Therapy
Dual-vector delivery system designed to deliver the large ABCA4 gene
-
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Zimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
